In most solid tumors, high levels of tumor-infiltrating CD8+ T cells predict good clinical outcomes after treatment, while immune exclusion or an immune desert phenotype is associated with resistance to multiple therapies (Chen and Mellman 2017; Fridman et al. The gene discussed is CD8A; the disease is neoplasm.